Dyrupeg is a medicine used in patients with cancer to help with neutropenia (low levels of neutrophils, a type of white blood cell), which is a common side effect of cancer treatment and can leave patients vulnerable to infections. It is given specifically to reduce the duration of neutropenia and prevent febrile neutropenia (neutropenia accompanied by fever) in patients treated with cytotoxic chemotherapy (a type of cancer treatment that kills cancer cells). Dyrupeg is not intended for use in patients with the blood cancer chronic myeloid leukaemia or with myelodysplastic syndromes (conditions in which large numbers of abnormal blood cells are produced, which can develop into leukaemia). Dyrupeg contains the active substance pegfilgrastim and is a biological medicine. It is a ‘biosimilar medicine’; this means that Dyrupeg is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the European Union (EU). The reference medicine for Dyrupeg is Neulasta.
Therapeutic Indication
Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
Therapeutic Area (MeSH)
ATC Code
L03AA13
ATC Item
N/A
Pharmacotherapeutic Group
Immunostimulants
Active Substance (Summary)
INN / Common Names
EMA Name
Dyrupeg
Medicine Name
Dyrupeg
Aliases
N/ANo risk management plan link.
